De Novo CD5+ Primary Gastrointestinal Diffuse Large B-Cell Lymphoma: Challenges With Treatment and Clinical Course

Authors

Preethi Ramachandran
Sonu Sahni
Jen-Chin Wang, New York Medical College

DOI

10.1177/2324709619893546

Journal Title

Journal of Investigative Medicine High Impact Case Reports

First Page

2324709619893546

Last Page

2324709619893546

Document Type

Article

Publication Date

1-1-2019

Department

Medicine

Abstract

The gastrointestinal tract is a common extranodal site for lymphomas. However, primary gastrointestinal lymphomas are rare. Diffuse large B-cell lymphomas (DLBCL) are the most commonly encountered type in the gastrointestinal tract. Most of the DLBCL are CD5 negative. CD5+ DLBCL is very rare and a poor prognostic subtype of lymphoma. We report a rare case of primary small bowel CD5+ DLBCL that evolved from being a localized low International Prognostic Index-scored disease into an advanced and aggressive disease primarily dictated by the presence of CD5 antigen positivity.

Recommended Citation

Ramachandran, P., Sahni, S., & Wang, J. (2019). De Novo CD5+ Primary Gastrointestinal Diffuse Large B-Cell Lymphoma: Challenges With Treatment and Clinical Course. Journal of Investigative Medicine High Impact Case Reports, 7, 2324709619893546-2324709619893546. https://doi.org/10.1177/2324709619893546